Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Transforming growth factor-β (TGF-β) plays a crucial role in the pathogenesis of Systemic Sclerosis (SSc) and other fibrotic disorders. TGF-β-mediated c-Abl and Src kinase activation induces strong profibrotic cascade signaling. The purpose of this study was to test in vivo the antifibrotic activity...
Main Authors: | Peter J Wermuth, Sergio A Jimenez |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5931634?pdf=render |
Similar Items
-
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
by: Nicholas M Levinson, et al.
Published: (2012-01-01) -
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
by: El Rassi F, et al.
Published: (2013-08-01) -
Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity
by: Natalia I. Moguillansky, MD, et al.
Published: (2017-01-01) -
A Src-Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth and metastasis in vitro and in vivo /
by: Jallal, Houda.
Published: (2007) -
Bosutinib in the management of chronic myelogenous leukemia
by: Keller-von Amsberg G, et al.
Published: (2013-05-01)